Tradestie Institutional Equity Comparison Engine

MRNA vs BIIB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BIIB Overall Edge

BIIB Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BIIB at 15.6x Forward P/E and 23.5% operating margin (+10.6% YoY). In options structure, MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BIIB
MRNA 23.0x vs BIIB 15.6x Fwd P/E
Growth & Margin Winner BIIB
Op Margin -80.8% vs 23.5% ยท YoY +29.2% vs +10.6%
Momentum & Technical Winner MRNA
1Y +765.2% vs +53.4% ยท 52W Pos 75% vs 92%
Options & Structure Winner BIIB
CONSOLIDATION (30th %ile IV) vs CONSOLIDATION (6th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
1M Return -0.94%
1Y Return +765.2%
Forward P/E 23.0x
Unified AI Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1
BIIB NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
1M Return +8.63%
1Y Return +53.41%
Forward P/E 15.6x
Unified AI Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +765.2% BIIB +53.41% Spread: +711.79 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue BIIB Revenue MRNA Op. Margin BIIB Op. Margin Margin Edge
FY2018 $140M $13.4B -306.0% 43.8% BIIB
FY2019 $60M $14.4B -906.8% 49.0% BIIB
FY2020 $800M $13.4B -95.0% 33.8% BIIB
FY2021 $18.5B $11.0B 72.0% 25.9% MRNA
FY2022 $19.3B $10.2B 48.9% 29.9% MRNA
FY2023 $6.85B $9.84B -61.9% 11.8% BIIB
FY2024 $3.24B $9.68B -121.9% 16.9% BIIB
FY2025 $1.94B $9.89B -158.1% 13.1% BIIB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (3) vs BIIB (7)
Institutional Metric MRNA BIIB Criterion Row Winner
Market Capitalization Scale $93.6B $37.0B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 109.9x Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x 15.6x Lower Multiple BIIB
Revenue Growth (YoY) Growth +29.2% +10.6% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 23.5% Higher Margin BIIB
Net Profit Margin Profitability -110.5% 3.4% Higher Margin BIIB
Return on Equity (ROE) Capital Efficiency -34.5% 1.9% Higher ROE BIIB
52-Week Range Position Momentum 75% ($22โ€“$281) 92% ($160โ€“$261) Stronger Trend BIIB
Beta / 30D Volatility Risk Regime 2.35ฮฒ ยท 101% Vol 0.27ฮฒ ยท 36% Vol Lower Realized Risk BIIB
Unified Institutional Score Composite Signal 46.8 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite BIIB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs BIIB Buy Guide
MRNA CONSOLIDATION
18d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live BIIB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor BIIB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.